Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Gene | CHEK2 |
Variant | R3W |
Impact List | missense |
Protein Effect | unknown |
Gene Variant Descriptions | CHEK2 R3W does not lie within any known functional domains of the Chek2 protein (UniProt.org). The functional effect of R3W is conflicting, as it results in cell proliferation similar to wild-type Chek2 in a yeast assay in one study (PMID: 30851065), however, results in intermediate cell proliferation relative to wild-type Chek2 in another study (PMID: 22419737), and similar Kap1 phosphorylation at serine (S)-473 in cell culture and in vitro assays (PMID: 31050813), and therefore, its effect on Chek2 protein function is unknown. |
Associated Drug Resistance | |
Category Variants Paths |
CHEK2 mutant CHEK2 R3W |
Transcript | NM_007194.4 |
gDNA | chr22:g.28734715G>A |
cDNA | c.7C>T |
Protein | p.R3W |
Source Database | RefSeq |
Genome Build | GRCh38/hg38 |
Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
---|---|---|---|---|---|
XM_011529842 | chr22:g.28737277T>A | c.7A>T | p.R3W | RefSeq | GRCh38/hg38 |
XM_011529844.3 | chr22:g.28737277T>A | c.7A>T | p.R3W | RefSeq | GRCh38/hg38 |
NM_007194 | chr22:g.28734715G>A | c.7C>T | p.R3W | RefSeq | GRCh38/hg38 |
XM_047441107.1 | chr22:g.28737277T>A | c.7A>T | p.R3W | RefSeq | GRCh38/hg38 |
NM_007194.4 | chr22:g.28734715G>A | c.7C>T | p.R3W | RefSeq | GRCh38/hg38 |
XM_017028560.1 | chr22:g.28737277T>A | c.7A>T | p.R3W | RefSeq | GRCh38/hg38 |
XM_011529842.3 | chr22:g.28737277T>A | c.7A>T | p.R3W | RefSeq | GRCh38/hg38 |
XM_011529840 | chr22:g.28737277T>A | c.7A>T | p.R3W | RefSeq | GRCh38/hg38 |
XM_024452148.2 | chr22:g.28737277T>A | c.7A>T | p.R3W | RefSeq | GRCh38/hg38 |
XM_011529839.3 | chr22:g.28737277T>A | c.7A>T | p.R3W | RefSeq | GRCh38/hg38 |
NM_007194.3 | chr22:g.28734715G>A | c.7C>T | p.R3W | RefSeq | GRCh38/hg38 |
XM_011529842.2 | chr22:g.28737277T>A | c.7A>T | p.R3W | RefSeq | GRCh38/hg38 |
XM_011529840.3 | chr22:g.28737277T>A | c.7A>T | p.R3W | RefSeq | GRCh38/hg38 |
XM_024452149.1 | chr22:g.28737277T>A | c.7A>T | p.R3W | RefSeq | GRCh38/hg38 |
NM_001005735 | chr22:g.28734715G>A | c.7C>T | p.R3W | RefSeq | GRCh38/hg38 |
NM_145862.2 | chr22:g.28734715G>A | c.7C>T | p.R3W | RefSeq | GRCh38/hg38 |
XM_011529841 | chr22:g.28734715G>A | c.7C>T | p.R3W | RefSeq | GRCh38/hg38 |
XM_011529839.2 | chr22:g.28737277T>A | c.7A>T | p.R3W | RefSeq | GRCh38/hg38 |
XM_011529841.1 | chr22:g.28734715G>A | c.7C>T | p.R3W | RefSeq | GRCh38/hg38 |
XM_011529844.2 | chr22:g.28737277T>A | c.7A>T | p.R3W | RefSeq | GRCh38/hg38 |
NM_001005735.1 | chr22:g.28734715G>A | c.7C>T | p.R3W | RefSeq | GRCh38/hg38 |
XM_011529844 | chr22:g.28737277T>A | c.7A>T | p.R3W | RefSeq | GRCh38/hg38 |
XM_047441105.1 | chr22:g.28734715G>A | c.7C>T | p.R3W | RefSeq | GRCh38/hg38 |
XM_017028560.2 | chr22:g.28737277T>A | c.7A>T | p.R3W | RefSeq | GRCh38/hg38 |
XM_011529843 | chr22:g.28734715G>A | c.7C>T | p.R3W | RefSeq | GRCh38/hg38 |
NM_001349956.1 | chr22:g.28734715G>A | c.7C>T | p.R3W | RefSeq | GRCh38/hg38 |
NM_145862.2 | chr22:g.28734715G>A | c.7C>T | p.R3W | RefSeq | GRCh38/hg38 |
NM_145862 | chr22:g.28734715G>A | c.7C>T | p.R3W | RefSeq | GRCh38/hg38 |
NM_001005735.2 | chr22:g.28734715G>A | c.7C>T | p.R3W | RefSeq | GRCh38/hg38 |
NM_001349956.2 | chr22:g.28734715G>A | c.7C>T | p.R3W | RefSeq | GRCh38/hg38 |
XM_017028560 | chr22:g.28737277T>A | c.7A>T | p.R3W | RefSeq | GRCh38/hg38 |
XM_011529839 | chr22:g.28737277T>A | c.7A>T | p.R3W | RefSeq | GRCh38/hg38 |
XM_024452148.1 | chr22:g.28737277T>A | c.7A>T | p.R3W | RefSeq | GRCh38/hg38 |
XM_047441106.1 | chr22:g.28734715G>A | c.7C>T | p.R3W | RefSeq | GRCh38/hg38 |
XM_024452149.2 | chr22:g.28737277T>A | c.7A>T | p.R3W | RefSeq | GRCh38/hg38 |
XM_011529840.4 | chr22:g.28737277T>A | c.7A>T | p.R3W | RefSeq | GRCh38/hg38 |
XM_047441104.1 | chr22:g.28734715G>A | c.7C>T | p.R3W | RefSeq | GRCh38/hg38 |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
CHEK2 mutant | Advanced Solid Tumor | no benefit | Olaparib | Phase II | Actionable | In a Phase II trial, Lynparza (olaparib) treatment did not demonstrate clinical activity in patients with advanced solid tumors harboring ATM (n=13) or CHEK2 (n=14) mutations (Ann Oncol (2023) 34 (suppl_2): S242; NCT03967938). | detail... |
CHEK2 mutant | prostate cancer | not applicable | N/A | Guideline | Risk Factor | Germline CHEK2 mutations are associated with increased risk of developing prostate cancer (NCCN.org). | detail... |
CHEK2 mutant | breast cancer | no benefit | Olaparib | Case Reports/Case Series | Actionable | In a Phase II trial (TBCRC 048), Lynparza (olaparib) treatment did not result in an objective response in 7 patients with metastatic breast cancer harboring only germline mutations in CHEK2 (PMID: 33119476; NCT03344965). | 33119476 |
CHEK2 mutant | breast cancer | not applicable | N/A | Guideline | Risk Factor | Germline CHEK2 mutations are associated with increased risk of developing breast cancer (NCCN.org). | detail... |